Large intestine–targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection-Reference-Cited by-同舟云学术

Large intestine–targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection

Published:2012-07-15 Issue:8 Volume:18 Page:1291-1296
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Zhu Qing,Talton James,Zhang Guofeng,Cunningham Tshaka,Wang Zijian,Waters Robert C,Kirk James,Eppler Bärbel,Klinman Dennis M,Sui Yongjun,Gagnon Susan,Belyakov Igor M,Mumper Russell J,Berzofsky Jay A

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2866.pdf

Reference32 articles.

1. Belyakov, I.M. et al. The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102, 2072–2081 (1998).

2. Belyakov, I.M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7, 1320–1326 (2001).

3. Belyakov, I.M., Isakov, D., Zhu, Q., Dzutsev, A. & Berzofsky, J.A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J. Immunol. 178, 7211–7221 (2007).

4. Zhu, Q. et al. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal Immunol. 1, 78–88 (2008).

5. Critchfield, J.W. et al. Magnitude and complexity of rectal mucosa HIV-1–specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS ONE 3, e3577 (2008).

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioinspired and bioderived nanomedicine for inflammatory bowel disease;WIREs Nanomedicine and Nanobiotechnology;2024-07

2. Oral Vaccines for Prevention of Bacterial Infections: Development Strategies and Prospects;Problems of Particularly Dangerous Infections;2024-06-25

3. Oral Vaccine Delivery;Nanocarrier Vaccines;2024-02-16

4. Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19;Microbial Cell Factories;2024-02-06

5. Oral immunization with acidified sucralfate@N-2-HACC/CMCS NPs elicits protective immune response in guinea pigs;2024-01-10